Implementing a Sodium-Glucose Cotransporter 2 Inhibitor Module With a Software Tool (Future Health Today): Qualitative Study

被引:1
作者
Suen, Matthew [1 ]
Manski-Nankervis, Jo -Anne [1 ]
McBride, Caroline [1 ]
Lumsden, Natalie [1 ]
Hunter, Barbara [1 ]
机构
[1] Univ Melbourne, Dept Gen Practice & Primary Care, Level 3,North Wing,Bldg,181 Grattan St,Med Bldg, Parkville 3010, Australia
关键词
type; 2; diabetes; CP-FIT; electronic health; clinical decision support tool; primary care; SGLT2; inhibitor; complication; tool; digital health intervention; thematic analysis; decision support; diabetes management; CLINICAL DECISION-SUPPORT; PRIMARY-CARE; MANAGEMENT;
D O I
10.2196/50737
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background: Primary care plays a key role in the management of type 2 diabetes. Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been demonstrated to reduce hospitalization and cardiac and renal complications. Tools that optimize management, including appropriate prescribing, are a priority for treating chronic diseases. Future Health Today (FHT) is software that facilitates clinical decision support and quality improvement. FHT applies algorithms to data stored in electronic medical records in general practice to identify patients who are at risk of a chronic disease or who have a chronic disease that may benefit from intensification of management. The platform continues to evolve because of rigorous evaluation, continuous improvement, and expansion of the conditions hosted on the platform. FHT currently displays recommendations for the identification and management of chronic kidney disease, cardiovascular disease, type 2 diabetes, and cancer risk. A new module will be introduced to FHT focusing on SGLT2 inhibitors in patients with type 2 diabetes who have chronic kidney diseases, cardiovascular diseases, or risk factors for cardiovascular disease. Objective: The study aims to explore the barriers and enablers to the implementation of an SGLT2 inhibitor module within the Future Health Today software. Methods: Clinic staff were recruited to participate in interviews on their experience in their use of a tool to improve prescribing behavior for SGLT2 inhibitors. Thematic analysis was guided by Clinical Performance Feedback Intervention Theory. Results: In total, 16 interviews were completed. Identified enablers of use included workflow alignment, clinical appropriateness, and active delivery of the module. Key barriers to use were competing priorities, staff engagement, and knowledge of the clinical topic. Conclusions: There is a recognized benefit to the use of a clinical decision support tool to support type 2 diabetes management, but barriers were identified that impeded the usability and actionability of the module. Successful and effective implementation of this tool could support the optimization of patient management of type 2 diabetes in primary care.
引用
收藏
页数:8
相关论文
共 50 条
  • [31] Sodium-Glucose Cotransporter-2 Inhibitor Prevents Stroke in Patients With Diabetes and Atrial Fibrillation
    Chang, Sheng-Nan
    Chen, Jien-Jiun
    Huang, Pang-Shuo
    Wu, Cho-Kai
    Wang, Yi-Chih
    Hwang, Juey-Jen
    Tsai, Chia-Ti
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2023, 12 (10):
  • [32] Metabolite profiling and enzyme reaction phenotyping of luseogliflozin, a sodium-glucose cotransporter 2 inhibitor, in humans
    Miyata, Atsunori
    Hasegawa, Masatoshi
    Hachiuma, Kenji
    Mori, Haruyuki
    Horiuchi, Nobuko
    Mizuno-Yasuhira, Akiko
    Chino, Yukihiro
    Jingu, Shigeji
    Sakai, Soichi
    Samukawa, Yoshishige
    Nakai, Yasuhiro
    Yamaguchi, Jun-ichi
    XENOBIOTICA, 2017, 47 (04) : 332 - 345
  • [33] Sodium-glucose Cotransporter 2 Inhibitors in Heart Failure: Potential Mechanisms of Action, Adverse Effects and Future Developments
    Tamargo, Juan
    EUROPEAN CARDIOLOGY REVIEW, 2019, 14 (01) : 23 - 32
  • [34] Sustained fasting glucose oxidation and postprandial lipid oxidation associated with reduced insulin dose in type 2 diabetes with sodium-glucose cotransporter 2 inhibitor: A randomized, open-label, prospective study
    Kanazawa, Ken
    Uchino, Hiroshi
    Shigiyama, Fumika
    Igarashi, Hiroyuki
    Ikehara, Kayoko
    Yoshikawa, Fukumi
    Usui, Shuki
    Miyagi, Masahiko
    Yoshino, Hiroshi
    Ando, Yasuyo
    Kumashiro, Naoki
    Hirose, Takahisa
    JOURNAL OF DIABETES INVESTIGATION, 2019, 10 (04) : 1022 - 1031
  • [35] Efficacy and Safety of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes
    Henry, Robert R.
    Thakkar, Payal
    Tong, Cindy
    Polidori, David
    Alba, Maria
    DIABETES CARE, 2015, 38 (12) : 2258 - 2265
  • [36] Nonclinical Toxicology Assessments Support the Chronic Safety of Dapagliflozin, a First-in-Class Sodium-Glucose Cotransporter 2 Inhibitor
    Tirmenstein, Mark
    Dorr, Thomas E.
    Janovitz, Evan B.
    Hagan, Deborah
    Abell, Lynn M.
    Onorato, Joelle M.
    Whaley, Jean M.
    Graziano, Michael J.
    Reilly, Timothy P.
    INTERNATIONAL JOURNAL OF TOXICOLOGY, 2013, 32 (05) : 336 - 350
  • [37] Sodium-glucose cotransporter-2 inhibitor therapy in kidney transplant patients with type 2 or post-transplant diabetes: an observational multicentre study
    Fructuoso, Ana I. Sanchez
    Raba, Andrea Bedia
    Deras, Eduardo Banegas
    Sanchez, Luis A. Vigara
    San Cecilio, Rosalia Valero
    Esteve, Antonio Franco
    Vega, Leonidas Cruzado
    Martinez, Eva Gavela
    Garcia, Maria E. Gonzalez
    Coronado, Pablo Saurdy
    Morales, Nancy D. Valencia
    Larrondo, Sofia Zarraga
    Cano, Natalia Ridao
    Blanca, Auxiliadora Mazuecos
    Marrero, Domingo Hernandez
    Castello, Isabel Beneyto
    Ramos, Javier Paul
    Ochoa, Adriana Sierra
    Molas, Carmen Facundo
    Roncero, Francisco Gonzalez
    Ramirez, Armando Torres
    Guldris, Secundino Cigarran
    Flores, Isabel Perez
    CLINICAL KIDNEY JOURNAL, 2023, : 1022 - 1034
  • [38] Amelioration of pancreatic fat accumulation in Japanese type 2 diabetes patients treated with sodium-glucose cotransporter 2 inhibitors: a retrospective study
    Horii, Tomomi
    Kozawa, Junji
    Fujita, Shingo
    Hosokawa, Yoshiya
    Kimura, Takekazu
    Fujita, Yukari
    Tokunaga, Ayumi
    Fukui, Kenji
    Shimomura, Iichiro
    OBESITY SCIENCE & PRACTICE, 2021, 7 (03): : 346 - 352
  • [39] Sodium-Glucose Cotransporter 2 Inhibitors: A Case Study in Translational Research
    Beitelshees, Amber L.
    Leslie, Bruce R.
    Taylor, Simeon I.
    DIABETES, 2019, 68 (06) : 1109 - 1120
  • [40] Effects of the sodium-glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure
    Kolwelter, Julie
    Bosch, Agnes
    Jung, Susanne
    Stabel, Lena
    Kannenkeril, Dennis
    Ott, Christian
    Bramlage, Peter
    Schiffer, Mario
    Achenbach, Stephan
    Schmieder, Roland E.
    ESC HEART FAILURE, 2022, 8 (06): : 5327 - 5337